Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

257 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-01

Study Completion Date

2020-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to associate dose of thromboprophylaxis with outcome in critically ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with 28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half of July and we will ad the outcome of 90-day mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

NCT04412304

Covid-19 Thromboembolic Events Bleeding

COMPLETED

Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

NCT05036824

Covid19 Hospitalization

UNKNOWN

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

NCT04409834

COVID-19 Venous Thromboembolism Arterial Thrombosis

COMPLETED PHASE4

COVID-19 and Venous Thromboembolism Risk

NCT04569344

Venous Thromboembolism Covid19

COMPLETED

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19

NCT04367831

COVID-19 Venous Thromboses Arterial Thrombosis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low dose thromboprophylaxis

Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin

Dose of tinzaparin or dalteparin

Intervention Type DRUG

The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

medium dose thromboprophylaxis

Daily dose of \>4500 IU but \<175 IU/kg of body weight tinzaparin or \>5000 IU but \<200 IU/kg of body weight dalteparin

Dose of tinzaparin or dalteparin

Intervention Type DRUG

The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

high dose thromboprophylaxis

Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin

Dose of tinzaparin or dalteparin

Intervention Type DRUG

The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dose of tinzaparin or dalteparin

The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Innohep/Fragmin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* laboratory confirmed positive test for SARS-CoV-2
* admitted to ICU because of respiratory failure caused by Covid-19

Exclusion Criteria

* patients with treatment for thromboembolic complications at arrival to the ICU
* short ICU length of stay defined as discharged the same date as ICU admission
* patients without initial thromboprophylaxis

Eligible Sex

ALL

Accepts Healthy Volunteers

No